47 completed, 11 terminated, 5 withdrawn, 4 active not recruiting. 45 Phase 2, 13 Phase 1, 5 Phase 3, 3 Not applicable.
Follow Carcinoma, Islet Cell: new trials by email Literature Review of Carcinoma, Islet Cell trials Research Report on Carcinoma, Islet Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Assessment of What Patients and Healthcare Providers Value Survey Administration - Gastric Adenocarcinoma, Pancreatic Adenocarcinoma | Completed | M.D. Anderson Cancer Center | 397 | 2020-06-11 | 2022-08-31 | |
| Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin Fluorouracil, Leucovorin, Liposomal Irinotecan - Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 11 | 2019-06-17 | 2025-01-30 |
| DOTATOC PET/CT for Imaging NET Patients 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT - Neuroendocrine Tumors, Insulinoma | Active not recruiting | British Columbia Cancer Agency | 800 | 2018-07-11 | 2026-05-12 | |
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study Distal Pancreatectomy Sealing Using LTW - Pancreatic Tumor, Benign, Pancreatic Neoplasms | Phase 1 | Completed | Laser Tissue Welding, Inc. | 11 | 2018-01-01 | 2022-04-06 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Sapanisertib - Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2 | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2017-04-28 | 2023-10-17 |
| FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF) - Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 2 | 2017-02-01 | 2020-11-27 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers Blood Draw - Melanoma | Completed | Wolfram Samlowski | 150 | 2016-06-01 | 2017-07-26 | |
| Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas Capecitabine, Carboplatin, Cisplatin - Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 67 | 2015-11-06 | 2026-10-02 |
| A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Palbociclib - Pancreatic Neuroendocrine Cancer | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 21 | 2015-05-01 | 2018-01-23 |
| Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate - Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 84 | 2015-02-01 | 2025-04-20 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer BBI608, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 139 | 2014-08-01 | 2023-11-18 |
| Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2014-06-18 | 2020-03-23 |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
Showing 20 of 71. Sign in to see all of them.
Somatostatinoma (51) · Insulinoma (36) · Gastrinoma (35) · Glucagonoma (33) · Vipoma (23) · Adenoma, Islet Cell (21) · Neoplasms (15) · Pancreatic Neoplasms (14) · Carcinoma, Medullary (12) · Neuroendocrine Tumors (12) · Pheochromocytoma (12) · Neoplasm Metastasis (9) · Carcinoma, Hepatocellular (8) · Carcinoma, Renal Cell (8)
Adenocarcinoma (71) · Digestive System Diseases (71) · Endocrine System Diseases (71) · Neoplasms by Histologic Type (71) · Neoplasms by Site (71) · Neoplasms, Glandular and Epithelial (71) · Digestive System Neoplasms (70) · Endocrine Gland Neoplasms (70) · Pancreatic Diseases (69) · Carcinoma (68) · Neoplasms, Germ Cell and Embryonal (63) · Neuroectodermal Tumors (63) · Pancreatic Neoplasms (57) · Carcinoma, Neuroendocrine (56) · Neoplasms (56)
Everolimus (7) · Capecitabine (6) · Octreotide (6) · Temozolomide (6) · Fluorouracil (5) · Leucovorin (5) · Bevacizumab (4) · Oxaliplatin (3) · Sirolimus (3) · Sunitinib (3) · temsirolimus (3) · Acetates (2) · Biological Therapy (2) · Bortezomib (2) · Cisplatin (2)
National Cancer Institute (NCI) (14) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · ECOG-ACRIN Cancer Research Group (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Novartis Pharmaceuticals (3) · British Columbia Cancer Agency (2) · Eastern Cooperative Oncology Group (2) · Mayo Clinic (2) · Pfizer (2) · University of Southern California (2) · Vanderbilt-Ingram Cancer Center (2) · Yale University (2) · Academic and Community Cancer Research United (1) · Burzynski Research Institute (1)
United States (59) · Canada (8) · Spain (5) · France (4) · Germany (4) · United Kingdom (4) · Australia (3) · Belgium (3) · Italy (3) · Argentina (2) · Netherlands (2) · South Korea (2) · Sweden (2) · Taiwan (2) · Brazil (1)
Francois Benard, MD (2) · James Yao (2) · Leonard B. Saltz, MD (2) · Mary Mulcahy, MD (2) · Timothy Hobday (2) · Agustin Garcia (1) · Anthony W. Tolcher, MD (1) · Arkadiusz Dudek, MD (1) · Daniel Halperin (1) · Ebrahim Delpassand, M.D. (1) · Emily Bergsland (1) · Emily K. Bergsland, MD (1)
PMID 14673042, PMID 20847174, PMID 21306237, PMID 21831734, PMID 22480131, PMID 22722717, PMID 25318437, PMID 25488966, PMID 25900182, PMID 25956795, PMID 27020837, PMID 27836885, PMID 27924459, PMID 29161241, PMID 29853660, PMID 31969335, PMID 33362722, PMID 33411058, PMID 33835977, PMID 33882143, PMID 34380663, PMID 34716198, PMID 36260828, PMID 37702588, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 39863139, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42225102, PMID 42499790
P30CA016672 (4), N01CM62205 (3), U10CA180820 (3), N01CM00039 (2), P50CA102701 (2), U01CA076576 (2), U10CA021115 (2), N01CM00032 (1), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM17102 (1), N01CM17105 (1)